Deep Breeze Ltd., manufacturer of the FDA approved VRIxp™ & VRIxv™ lung
imaging systems, announced that it has received CE mark for its O-Plan
application extending the usefulness of Deep Breeze's revolutionary VRI™
technology to patients eligible for lung cancer resection. The
application has recently received the CE mark and it is used by thoracic
surgeons in European Union countries.
Responding to the market need for the elimination of radiation-based
imaging; the O-Plan application replaces nuclear perfusion scans that
are performed prior lung resections, with radiation-free VRIxp™
recordings. Deep Breeze Ltd. has developed the O-plan to be tailored
specifically for thoracic surgeons. Together with VRIxp™ test and the
O-Plan results, the surgeon can now with an improved accuracy predict
the operability of patients with lung malignancies. The O-plan’s
accuracy is based on clinical guidelines for post-surgery prediction,
and the VRIxp™’s regional lung imaging quantification tool’s reliability
to correlate with VQ Scan results. The specialist simply combines
VRIxp™’s results on any PC with the lung function results and the
intended surgery data, and at a touch of a button interactively plans
the lung surgery.
“Developing novel applications supporting VRIxp™’s recordings expands
the scope of our innovative imaging technology to the most demanding
applications. Receipt of the CE mark for the O-plan is yet another
milestone supporting Deep Breeze’s expertise in meeting the most
stringent quality & safety standards. Evidently, the initial
installations in Germany, Spain ,Turkey, Check Republic and in the
Russian Federation indicate that the O-plan will enjoy a successful EU
penetration.” said Dr. Miki Nagler, CEO, Deep Breeze Ltd.
One of the leading O-plan investigators, Prof. Juan Bautista Galdiz -
Cruces Hospital in Bilbao, Spain added: “Findings on 50 subjects suggest
that predictions based on lung function testing and VRIxp™ data
demonstrated a high accuracy in comparison to the actual postoperative
results. This correlation is likewise observed in relation to techniques
as the V/Q scan. This data suggests the inclusion of the VRIxp™ in the
evaluation PPO in patients intervened of lung cancer.”
View the O-plan application at the upcoming DGP Meeting (Mannheim), 18th
to the 21st of March, Booth no. 55.
Deep Breeze Ltd.
Annette Navon, Marcom Manager
+
972-4-6266650x129
annetten@deepbreeze.com